Anna Hung1,2,3, Kyung Min Lee4, Julie A Lynch4, Yanhong Li5,6, Pradeep Poonnen6,7, Olga V Efimova4, Bradley J Hintze5,6, Trudy Buckingham8, Candice Yong8, Brian Seal8, Michael J Kelley6,7, Shelby D Reed5,9,6. 1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. anna.hung@duke.edu. 2. Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA. anna.hung@duke.edu. 3. Department of Veteran Affairs Medical Center, Durham, NC, USA. anna.hung@duke.edu. 4. Department of Veteran Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA. 5. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. 6. Department of Veteran Affairs Medical Center, Durham, NC, USA. 7. Duke University Medical Center, Durham, NC, USA. 8. AstraZeneca, Gaithersburg, MD, USA. 9. Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Abstract
BACKGROUND: The Veterans Health Administration (VHA) is the largest integrated health care system in the United States (US). Among VHA patients, the rate of use of concurrent chemoradiation therapy (CCRT) among those with unresectable, stage III non-small cell lung cancer (NSCLC) is unknown. The objective was to report recent CCRT treatment patterns in VHA patients and identify characteristics associated with receipt of CCRT. METHODS: Using Department of Veteran Affairs (VA) Cancer Registry System data linked to VA electronic medical records, we determined rates of CCRT, sequential CRT (SCRT), radiation therapy (RT) only, chemotherapy (CT) only, and neither treatment. RESULTS: Among 4054 VHA patients who met study criteria, CCRT rates slightly increased from 44 to 50% between 2013 and 2017. Factors associated with decreased odds of CCRT receipt compared to any other treatment included increasing age (adjusted odds ratio [aOR] per 10 years = 0.67; 95% CI: 0.60-0.76) and Charlson-Deyo comorbidity score (aOR = 0.94; 95% CI: 0.91-0.97). White race was associated with increased odds of CCRT receipt (aOR = 1.24; 95% CI: 1.004-1.53). In a chart review sample of 200 patients, less than half (n = 85) had a documented reason for not receiving CCRT. Among these, 29% declined treatment, and 71% did not receive CCRT due to "not being a candidate" for reasons related to frailty or lung nodules being too far apart for radiation therapy. CONCLUSIONS: CCRT rates among VHA patients with unresectable, stage III NSCLC slightly increased from 2013 to 2017; however in 2017, only half were receiving CCRT. Older patients and those with multiple comorbidities were less likely to receive CCRT and even when controlling for these factors, non-white patients were less likely to receive CCRT.
BACKGROUND: The Veterans Health Administration (VHA) is the largest integrated health care system in the United States (US). Among VHA patients, the rate of use of concurrent chemoradiation therapy (CCRT) among those with unresectable, stage III non-small cell lung cancer (NSCLC) is unknown. The objective was to report recent CCRT treatment patterns in VHA patients and identify characteristics associated with receipt of CCRT. METHODS: Using Department of Veteran Affairs (VA) Cancer Registry System data linked to VA electronic medical records, we determined rates of CCRT, sequential CRT (SCRT), radiation therapy (RT) only, chemotherapy (CT) only, and neither treatment. RESULTS: Among 4054 VHA patients who met study criteria, CCRT rates slightly increased from 44 to 50% between 2013 and 2017. Factors associated with decreased odds of CCRT receipt compared to any other treatment included increasing age (adjusted odds ratio [aOR] per 10 years = 0.67; 95% CI: 0.60-0.76) and Charlson-Deyo comorbidity score (aOR = 0.94; 95% CI: 0.91-0.97). White race was associated with increased odds of CCRT receipt (aOR = 1.24; 95% CI: 1.004-1.53). In a chart review sample of 200 patients, less than half (n = 85) had a documented reason for not receiving CCRT. Among these, 29% declined treatment, and 71% did not receive CCRT due to "not being a candidate" for reasons related to frailty or lung nodules being too far apart for radiation therapy. CONCLUSIONS:CCRT rates among VHA patients with unresectable, stage III NSCLC slightly increased from 2013 to 2017; however in 2017, only half were receiving CCRT. Older patients and those with multiple comorbidities were less likely to receive CCRT and even when controlling for these factors, non-white patients were less likely to receive CCRT.
Authors: M A Socinski; J G Rosenman; J Halle; M J Schell; Y Lin; S Russo; M P Rivera; J Clark; S Limentani; R Fraser; W Mitchell; F C Detterbeck Journal: Cancer Date: 2001-09-01 Impact factor: 6.860
Authors: W Sause; P Kolesar; I V Taylor S; D Johnson; R Livingston; R Komaki; B Emami; W Curran; R Byhardt; A R Dar; A Turrisi Journal: Chest Date: 2000-02 Impact factor: 9.410
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox Journal: J Natl Cancer Inst Date: 2011-09-08 Impact factor: 13.506
Authors: R O Dillman; S L Seagren; K J Propert; J Guerra; W L Eaton; M C Perry; R W Carey; E F Frei; M R Green Journal: N Engl J Med Date: 1990-10-04 Impact factor: 91.245
Authors: T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; M Tarayre; M J Lacombe-Terrier; J Y Douillard; A Laplanche Journal: J Natl Cancer Inst Date: 1991-03-20 Impact factor: 13.506
Authors: Jimmy T Efird; Ethan J Anderson; Charulata Jindal; Thomas S Redding; Andrew D Thompson; Ashlyn M Press; Julie Upchurch; Christina D Williams; Yuk Ming Choi; Ayako Suzuki Journal: Int J Environ Res Public Health Date: 2021-12-31 Impact factor: 3.390